Wednesday, 25 July 2018

FDA panel votes against approval of GSK's lung disease drug

A U.S. Food and Drug Administration expert panel on Wednesday did not support approval of GlaxoSmithKline Plc's drug Nucala in treating a disease that limits airflow to the lungs.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)